SAH Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q53FZ2 |
---|---|
Clone Names | 80924189 |
Gene ID | 6296 |
---|---|
Other Names | Acyl-coenzyme A synthetase ACSM3, mitochondrial, Acyl-CoA synthetase medium-chain family member 3, Butyrate--CoA ligase 3, Butyryl-coenzyme A synthetase 3, Middle-chain acyl-CoA synthetase 3, Protein SA homolog, ACSM3, SAH |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6953b was selected from the C-term region of human SAH. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ACSM3 |
---|---|
Synonyms | SAH |
Function | Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism (PubMed:11772874). Capable of activating medium-chain fatty acids with a preference for isobutyrate among fatty acids with 2-6 carbon atoms (By similarity). |
Cellular Location | Mitochondrion. Mitochondrion matrix {ECO:0000250|UniProtKB:Q3UNX5} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SAH has medium-chain fatty acid:CoA ligase activity with broad substrate specificity (in vitro). Acts on acids from C(4) to C(11) and on the corresponding 3-hydroxy-and 2,3-or 3,4-unsaturated acids (in vitro).
References
Jin,Y., et.al., Hypertension 52 (2), E12-E13 (2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.